Jardiance® (empagliflozin) – New indication
December 2, 2016 – The FDA announced the approval of Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) tablets, to reduce the risk of cardiovascular (CV) death in adult patients with type 2 diabetes mellitus (T2DM) and CV disease.
Download PDF
